Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Status:
RECRUITING
Trial end date:
2029-03-24
Target enrollment:
Participant gender:
Summary
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.